Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Bloomberg Customers


February 12, 2016 5:09 AM ET

Pharmaceuticals

Company Overview of Viamet Pharmaceuticals, Inc.

Company Overview

Viamet Pharmaceuticals, Inc. discovers and develops novel antifungal agents through a proprietary medicinal chemistry platform. Its product includes VT-1161, an oral agent that is in Phase IIa clinical trials for the treatment of moderate to severe acute vulvovaginal candidiasis; and moderate to severe interdigital tinea pedis, a dermatologic infection. The company is also developing VT-1129, an oral agent for the treatment of cryptococcal meningitis, an invasive fungal infection of the lining of the brain and spinal cord; and VT-1598 and related analogues, which are in preclinical development to identify the optimal candidate to advance in development as an oral and intravenous therapy for ...

4505 Emperor Boulevard

Suite 300

Durham, NC 27703

United States

Phone:

919-467-8539

Fax:

919-467-8540

Key Executives for Viamet Pharmaceuticals, Inc.

Chief Executive Officer, President and Director
Age: 54
Chief Business & Financial Officer
Age: 51
Chief Medical Officer
Compensation as of Fiscal Year 2015.

Viamet Pharmaceuticals, Inc. Key Developments

Viamet Pharmaceuticals Appoints Oren Cohen as Chief Medical Officer

Viamet Pharmaceuticals, Inc. announced the appointment of Oren Cohen, M.D., as Chief Medical Officer to further strengthen the company’s management team. Dr. Cohen is an authority on the development of drugs for the treatment of infectious diseases and multiple other indications. Prior to joining Viamet, Dr. Cohen served as Senior Vice President and Global Head, Early Clinical Development as well as Chief Medical Officer for Quintiles Inc., where he was involved in the oversight of over 200 industry-sponsored clinical trials across numerous therapeutic areas.

Viamet Pharmaceuticals, Inc. Receives QIDP Designation to VT-1129 for Treatment of Cryptococcal Meningitis

Viamet Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) designation to VT-1129, the company’s novel candidate for the treatment of cryptococcal meningitis. Created under the Generating Antibiotics Incentives Now (GAIN) Act of 2012, QIDP designation provides Viamet with significant incentives for the development of VT-1129, including the potential for priority review by the FDA, eligibility for fast-track status, and a five-year extension of marketing exclusivity under the Hatch-Waxman Act. The company also announced that VT-1129 will be highlighted in two presentations at the 2015 American Society for Microbiology (ASM) Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) and International Society of Chemotherapy (ISC) International Congress of Chemotherapy and Infection (ICC).

Viamet Pharmaceuticals, Inc. and the Mycoses Study Group Education & Research Consortium Establish Collaboration to Advance Novel Therapy for Cryptococcal Meningitis

Viamet Pharmaceuticals, Inc. and the Mycoses Study Group Education & Research Consortium announced the establishment of a strategic collaboration to advance a novel therapy for cryptococcal meningitis and other life-threatening fungal infections. This collaboration will combine the antifungal drug discovery and development expertise of Viamet with the strategic clinical development expertise of the MSGERC. Cryptococcal meningitis is a life-threatening invasive fungal infection of the brain and spinal cord that occurs most often in immunocompromised patients, including those with HIV infection, transplant recipients and oncology patients. In preclinical studies, VT-1129 has demonstrated the ability to completely eradicate the fungal pathogen that causes cryptococcal meningitis from the central nervous system.

Similar Private Companies By Industry

Company Name Region
Douglas Industries, Inc. United States
Parion Sciences, Inc. United States
HWSM Pharmaceuticals, L.L.C. United States
Zeneca Wilmington Inc. United States
MicroDisc Technologies, Inc. United States

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Viamet Pharmaceuticals, Inc., please visit www.viamet.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.